Navigation Links
Helicobacter pylori Antibiotic Treatment of Peptic Ulcer May not Prevent Gastric lymphomas

Stanford, CA -- Successful eradication of Helicobacter may not prevent future aggressive gastric lymphoma since resting B cells are left behind. This was reported by Research led by Dr. Anne Mueller at Stanford University // School of Medicine.

The paper by Mueller et al., "The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of Helicobacter-induced MALT lymphoma," appears in the September issue of The American Journal of Pathology.

Helicobacter pylori, a spiral bacterium of the stomach, infects more than half of the world's population. It is now widely accepted that, aside from gastritis and ulcers, H. pylori is also a causative agent of gastric lymphoma, specifically gastric B cell lymphoma of mucosa-associated lymphoid tissue (MALT). While antibiotic treatment eradicates the bacteria and promotes tumor regression, the effects of re-infection on disease are more severe.

Dr. Mueller's group used a mouse model of Helicobacter-induced MALT lymphoma that employs H. felis to mimic human disease in the mouse. Mice were infected with H. felis and maintained for 18 months before being assigned to one of three treatment groups: 1) no treatment (primarily infected), 2) antibiotic therapy to eradicate bacteria, or 3) antibiotic therapy followed by re-infection.

As expected, low-grade MALT lymphoma occurred in 35% of all infected animals. However, frank MALT lymphoma was more prevalent in re-infected animals (44%) than in primarily infected animals (25%). The significance of the described work is that gastric lymphoma progresses more rapidly upon secondary infection. Because resting B cells are left behind following antibiotic treatment, re-infection by H. pylori promotes the existing B cells to progress quickly into tumors. Therefore, it is important that treated patients be carefully monitored for H. pylori re-infection.

Ref: Mueller O 'Rourke J, Chu P, Chu A, Dixon MF, Bouley DM, Lee A , Falkow S: The role of antigenic drive and tumor-infiltrating accessory cells in the pathogenesis of Helicobacter-induced MALT lymphoma. Am J Pathol 2005, 167:797-812

Research was supported by the National Institutes of Health (US), the Emmy-Noether-Program of the Deutsche Forschungsgemeinschaft (Germany), and J National Health and Medical Research Council (Australia).

Contact: Audra Cox acox@asip.org 301-634-7409 American Journal of Pathology

(Sourece: www.eurekalert.org)

Further Information on Medindia on H.Pylori:

H.Pylori testing recommended in patients with peptic ulcer: Researchers in the United States have found that the practice of testing and treating H.Pylori has steadily increased over the past 14 years. However, they suggested that patients with confirmed peptic ulcer disease should be tested for Helicobacter Pylori(H.Pylori) infection rather than receiving treatment for the infection as a matter of course. Testing was a more appropriate option than empiric treatment in patients with peptic ulcer disease, as the prevalence of H.Pylori was found to be only 36 percent.

Click here to read more:

http://www.medindia.net/news/view_news_main.asp?t=gn&x=1834
'"/>




Related medicine news :

1. Dietary cure for fighting Helicobacter pylori
2. Helicobacter pylori effectively killed by Sodium nitrite
3. Evidence supporting H.pylori eradication
4. Dietary cure for fighting Helicobacter pylori
5. Helicobacter pylori effectively killed by Sodium nitrite
6. Receptor for H.pylori Identified in Stomach
7. Antibiotics Dangerous for Diarrhoea in Children Caused by E.Coli
8. Antibiotics Helps Autism
9. Antibiotics losing their power against acne
10. Antibiotic induces liver damage in children with E.COLI infections.
11. Antibiotics help heart patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will ... Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the ... beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 business, civic, ... to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural event, ... and operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee University, ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... 2016 , ... The annual time frame to change Medicare health and prescription ... December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan ... to make changes during this period order for their new policy to go into ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain ... an injury, patients must find the one that works for them. When an inventor ... a machine that worked and decided to share it with others. , He developed ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... British Columbia , December 2, 2016 bioLytical ... bekannt gegeben, ab diesem Monat seinen  INSTI HIV-Selbsttests  in einer Version mit ... ... New: INSTI Self Test! ... , ,      (Photo: ...
(Date:12/2/2016)... The iShares Nasdaq Biotechnology Exchange-Traded Fund ... victory early in November. Less political risk has boosted ... predicting an uptick in M&A activities. Today, Stock-Callers.com takes ... they have fared at the last close: Celldex Therapeutics ... (NASDAQ: FOLD ), Navidea Biopharmaceuticals Inc. (NYSE ...
(Date:11/30/2016)... Nov 30, 2016 Research and ... Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices 2017 - ... ... The full report suite on the U.S. market ... drainage systems, intracranial pressure monitoring devices, detachable coils, liquid embolics, ...
Breaking Medicine Technology: